Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Stefanie Hieke-Schulz"'
Autor:
Herbert Schreiber, Iris-Katharina Penner, Tanja Maier, Stefanie Hieke-Schulz, Jost Leemhuis, Tjalf Ziemssen
Publikováno v:
Journal of Central Nervous System Disease, Vol 16 (2024)
Background Best supportive care (BSC) measures are an essential component for the management of primary progressive multiple sclerosis (PPMS). Objectives RETRO PPMS (ML39631) is the first study to systematically analyze the therapeutic journey and st
Externí odkaz:
https://doaj.org/article/a186cc90843e4577891e37c3c036ce53
Autor:
Martin S. Weber, Mathias Buttmann, Sven G. Meuth, Petra Dirks, Erwan Muros-Le Rouzic, Julius C. Eggebrecht, Stefanie Hieke-Schulz, Jost Leemhuis, Tjalf Ziemssen
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundReal-world relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) populations may be more diverse than in clinical trials. Here, we present a first analysis of safety, adherence and persistence data from a real-world cohort of
Externí odkaz:
https://doaj.org/article/5c361ada58c94ccf8af5b50ba90fce7e
Autor:
Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser, Tjalf Ziemssen
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overal
Externí odkaz:
https://doaj.org/article/d8e9e8de57af437a984b0d10fb418cba
Autor:
Mathias Mäurer, Klaus Tiel-Wilck, Eckard Oehm, Nils Richter, Michael Springer, Patrick Oschmann, Arndt Manzel, Stefanie Hieke-Schulz, Vera Zingler, Julia A. Kandenwein, Tjalf Ziemssen, Ralf A. Linker
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 12 (2019)
Background: With a large array of disease modifying therapies (DMTs) for relapsing-remitting MS (RRMS), identifying the optimal treatment option for the individual patient is challenging and switching of immunotherapies is often required. The objecti
Externí odkaz:
https://doaj.org/article/0fd09a02da39460790244fd7336013fa
Autor:
David Wormser, Jost Leemhuis, Stefanie Hieke-Schulz, Vera Zingler, Tjalf Ziemssen, Petra Dirks, Heike Berthold
Publikováno v:
BMC Neurology, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Neurology
BMC Neurology
Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overall patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a2dce40c5be5a2c019d04ace91075f
http://link.springer.com/article/10.1186/s12883-020-01667-7
http://link.springer.com/article/10.1186/s12883-020-01667-7
Autor:
Wilko Weichert, Daniel-Christoph Wagner, Annette Lebeau, Johannes Ammann, Marion Kiechle, Hans Kreipe, Gustavo B. Baretton, Aurelia Noske, Wilfried Roth, Katja Steiger, Stefanie Hieke-Schulz, Peter Sinn, Carsten Denkert
Publikováno v:
Geburtshilfe und Frauenheilkunde.
Background Atezolizumab (an anti–PD-L1 antibody) has shown clinical activity alone or in combination with nab-paclitaxel in patients (pts) with first-line metastatic TNBC who have PD-L1 expression on their tumour-infiltrating immune cells (IC). We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9b9c613a722c116609591b3d4811f6
https://doi.org/10.1055/s-0040-1714600
https://doi.org/10.1055/s-0040-1714600
Autor:
Wilko Weichert, Peter Sinn, Ulrich Sommer, Gustavo B. Baretton, Aurelia Noske, Mike Flores, Katja Steiger, Carsten Denkert, Hans-Heinrich Kreipe, Daniel-Christoph Wagner, Annette Lebeau, Marion Kiechle, Wilfried Roth, Stefanie Hieke-Schulz, Johannes Ammann
Publikováno v:
HistopathologyReferences. 78(4)
AIMS Studies in various cancer types have demonstrated discordance between results from different programmed death-ligand 1 (PD-L1) assays. Here, we compare the reproducibility and analytical concordance of four clinically developed assays for assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe70bf23ff4ffe3df9e8f9685426cbfe
https://pubmed.ncbi.nlm.nih.gov/32936950
https://pubmed.ncbi.nlm.nih.gov/32936950
Autor:
Mike Flores, Wilfried Roth, Gustavo Baretton, Markus Eckstein, Till Braunschweig, Bernd Wullich, Stephan Macher-Göppinger, Ulrich Sommer, Manfred P. Wirth, Arndt Hartmann, Ruth Knüchel, Wilko Weichert, Stefanie Hieke-Schulz, Johannes Ammann, Greg Harlow, Kristina Schwamborn
Background Previous studies have suggested increased clinical benefit with inhibition of programmed death-ligand 1 (PD-L1)/programmed death-1 in patients with PD-L1–positive locally advanced/metastatic renal cell carcinoma (RCC). We examined the an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ab21dd93a705e056c1782bfbafa67c0
https://mediatum.ub.tum.de/doc/1585400/document.pdf
https://mediatum.ub.tum.de/doc/1585400/document.pdf
Autor:
Gustavo Baretton, Robert Tauber, Arndt Hartmann, Till Braunschweig, Ruth Knüchel, Franziska Erlmeier, Felix Lasitschka, Stefanie Hieke-Schulz, Kristina Schwamborn, Johannes Ammann, Peter Schirmacher, Wilko Weichert
Publikováno v:
Virchows Archiv 475(5), 599-608 (2019). doi:10.1007/s00428-019-02610-z
Virchows Archiv
Virchows Archiv
Virchows Archiv 475(5), 599-608 (2019). doi:10.1007/s00428-019-02610-z
Published by Springer, Berlin ; Heidelberg
Published by Springer, Berlin ; Heidelberg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5282a0367ac9af7bce4a429ef2b6a799
Autor:
Peter Sinn, Katja Steiger, Annette Lebeau, Daniel-Christoph Wagner, Johannes Ammann, Aurelia Noske, Wilko Weichert, Carsten Denkert, Stefanie Hieke-Schulz, Marion Kiechle, Wilfried Roth, Gustavo B. Baretton, Hans Kreipe
Publikováno v:
Annals of Oncology. 30:v130-v131
Background Atezolizumab (an anti–PD-L1 antibody) has shown clinical activity alone or in combination with nab-paclitaxel in patients (pts) with first-line metastatic TNBC who have PD-L1 expression on their tumour-infiltrating immune cells (IC). We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e7fe23b17f7adfdfe2cb588d97fd159
https://doi.org/10.1093/annonc/mdz242.054
https://doi.org/10.1093/annonc/mdz242.054